Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver

Cited by (418)

Items 101–200 of 418

1. Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation
   K. McNally, Richard Cotton, J. Cocker, Kate Jones, M. Bartels, D. Rick, P. Price, G. Loizou · 2012 · Journal of Toxicology
2. Structural pairwise comparisons of HLM stability of phenyl derivatives: Introduction of the Pfizer metabolism index (PMI) and metabolism-lipophilicity efficiency (MLE)
   Mark L. Lewis, L. Cucurull-Sanchez · 2008 · Journal of Computer-Aided Molecular Design
3. Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.
   R. Hines, Dana Sargent, H. Autrup, L. Birnbaum, R. Brent, N. Doerrer, E. Cohen Hubal, D. Juberg, C. Laurent, R. Luebke et al. · 2010 · Toxicological Sciences
4. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics
   D. Ramirez, K. Collins, Al Aradi, K. Conger, D. Gustafson · 2018 · Drug Metabolism And Disposition
5. Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data
   H. Nguyen, E. Kimoto, Ernesto Callegari, R. Obach · 2016 · Drug Metabolism And Disposition
6. Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics
   Matthew D. Harwood, Matthew R. Russell, Sibylle Neuhoff, Geoff Warhurst, Amin Rostami‐Hodjegan · 2014 · Drug Metabolism and Disposition
7. Reliability of human cryopreserved hepatocytes and liver microsomes asin vitrosystems to predict metabolic clearance
   Rowan A. Stringer, Paul L. Nicklin, James Brian. Houston · 2008 · Xenobiotica
8. In vitro-to-in vivo correlation of the skin penetration, liver clearance and hepatotoxicity of caffeine.
   M. Gajewska, A. Paini, J. Sala Benito, J. Burton, Andrew Paul Worth, C. Urani, H. Briesen, K. Schramm · 2015 · Food and Chemical Toxicology
9. Physiologically Based Toxicokinetic (PBTK) Modeling in Ecotoxicology
   K. Krishnan, T. Peyret · 2009 · Emerging topics in ecotoxicology
10. Ontogeny of Hepatic Glucuronidation; Methods and Results
    Elke H. J. Krekels, Meindert Danhof, Dick Tibboel, Catherijne A. J. Knibbe · 2012 · Current Drug Metabolism
11. Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?
    Rodrigo Cristofoletti, Nikunjkumar Patel, J. Dressman · 2016 · Journal of Pharmacy and Science
12. Formed and preformed metabolites: facts and comparisons
    K. Pang, M. Morris, Huadong Sun · 2008 · The Journal of pharmacy and pharmacology
13. An update on metabolism studies using human hepatocytes in primary culture
    Marı́a José Gómez-Lechón, José Vicente Castell, María Teresa Donato · 2008 · Expert Opinion on Drug Metabolism & Toxicology
14. Microsomal and cytosolic scaling factors in dog and human kidney cortex and application for in vitro-in vivo extrapolation of renal metabolic clearance
    D. Scotcher, S. Billington, Jay M. Brown, Christopher R. Jones, C. Brown, A. Rostami-Hodjegan, A. Galetin · 2017 · Drug Metabolism And Disposition
15. Protein expression of various hepatic uridine 5′‐diphosphate glucuronosyltransferase (UGT) enzymes and their inter‐correlations: a meta‐analysis
    B. Achour, A. Rostami-Hodjegan, J. Barber · 2014 · Biopharmaceutics & drug disposition
16. Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction
    S. Brantley, B. Gufford, R. Dua, Dj Fediuk, T. Graf, YV Scarlett, Kosea S. Frederick, M. Fisher, N. Oberlies, M. Paine · 2014 · CPT: Pharmacometrics & Systems Pharmacology
17. The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling
    J. Badée, S. Fowler, S. N. de Wildt, A. Collier, S. Schmidt, N. Parrott · 2018 · Clinical Pharmacokinetics
18. Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips
    R. Baudoin, Jean Matthieu Prot, Grégory Nicolas, Jessy Brocheton, Céline Brochot, Cécile Legallais, Henri Bénech, Éric Leclerc · 2012 · Xenobiotica
19. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
    Jeffry Adiwidjaja, A. Boddy, A. McLachlan · 2020 · Frontiers in Pharmacology
20. Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse
    Wei-Hsueh A. Chiu, Jerry L. Campbell, H. Clewell, Yi-Hui Zhou, F. Wright, K. Guyton, I. Rusyn · 2014 · Environmental Health Perspectives
21. Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog
    Aki T. Heikkinen, Arno Friedlein, Jens Lamerz, Peter Jakob, Paul Cutler, Stephen M. Fowler, Tara Williamson, Roberto Tolando, Thierry Lavé, Neil John Parrott · 2012 · Pharmaceutical Research
22. In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment.
    I. Rietjens, A. Punt, B. Schilter, G. Scholz, T. Delatour, P. van Bladeren · 2010 · Molecular Nutrition & Food Research
23. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
    J. Knaak, C. Dary, Xiaofei Zhang, R. Gerlach, R. Tornero-Velez, Daniel T. Chang, Rocky Goldsmith, J. Blancato · 2012 · Reviews of environmental contamination and toxicology
24. Fungal-selective resorcylate aminopyrazole Hsp90 inhibitors: optimization of whole-cell anticryptococcal activity and insights into the structural origins of cryptococcal selectivity
    Marcyk, Paul T., LeBlanc, Emmanuelle V., Kuntz, Douglas A., Xue, Alice, Ortiz, Francisco, Trilles, Richard, Bengtson, Stephen, Kenney, Tristan M. G., Huang, David S., Robbins, Nicole et al. · 2021 · Journal of Medicinal Chemistry
25. Physiologically based kinetic (PBK) modelling and human biomonitoring data for mixture risk assessment
    J. Pletz, Samantha Blakeman, A. Paini, Nikolaos Parissis, Andrew Paul Worth, A. Andersson, H. Frederiksen, A. Sakhi, C. Thomsen, S. Bopp · 2020 · Environment International
26. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards
    Hisham A El-Masri, Nicole Kleinstreuer, Ronald N. Hines, Linda D. Adams, Tamara L. Tal, Kristin Isaacs, Barbara A. Wetmore, Yu‐Mei Tan · 2016 · Toxicological Sciences
27. Local Kinetics and Dynamics of Xenobiotics
    O. Pelkonen, J. Kapitulnik, U. Gundert-Remy, AlanR Boobis, A. Stockis · 2008 · Critical Reviews in Toxicology
28. Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen.
    A. Péry, C. Brochot, F. Zeman, E. Mombelli, S. Desmots, M. Pavan, E. Fioravanzo, J. Zaldívar · 2013 · Toxicology Letters
29. Physiologically based kinetic modeling of bioactivation and detoxification of the alkenylbenzene methyleugenol in human as compared with rat.
    A. A. Al-Subeihi, B. Spenkelink, A. Punt, M. Boersma, P. van Bladeren, I. Rietjens · 2012 · Toxicology and Applied Pharmacology
30. Metabolism of α-thujone in human hepatic preparations in vitro
    Khaled Abass, Petri Reponen, Sampo Mattila, O. Pelkonen · 2011 · Xenobiotica; the fate of foreign compounds in biological systems
31. Reviews of Environmental Contamination and Toxicology
    D. M. Whitacre, M. Cavieres, C. Gerba, F. Günther · 2012
32. The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans.
    F. Storelli, Mengyue Yin, Aditya R. Kumar, M. K. Ladumor, R. Evers, Paresh P. Chothe, Osatohanmwen J. Enogieru, Xiao-Min Liang, Yu-Rong Lai, J. Unadkat · 2022 · Pharmacology and Therapeutics
33. Physiologically-Based Toxicokinetic Modeling of Zearalenone and Its Metabolites: Application to the Jersey Girl Study
    Dwaipayan Mukherjee, Steven G. Royce, Jocelyn A. Alexander, B. Buckley, S. Isukapalli, E. Bandera, H. Zarbl, P. Georgopoulos · 2014 · PLoS ONE
34. Development of a Highly Sensitive Method Using Liquid Chromatography-Multiple Reaction Monitoring to Quantify Membrane P-Glycoprotein in Biological Matrices and Relationship to Transport Function
    T. Miliotis, Liaqat Ali, J. Palm, A. Lundqvist, M. Ahnoff, T. Andersson, C. Hilgendorf · 2011 · Drug Metabolism And Disposition
35. Safety testing of metabolites: Expectations and outcomes.
    K. Pang · 2009 · Chemico-Biological Interactions
36. Comprehensive interpretation of in vitro micronucleus test results for 292 chemicals: from hazard identification to risk assessment application
    B. Kuo, Marc A. Beal, J. Wills, P. White, F. Marchetti, A. Nong, T. Barton-Maclaren, K. Houck, C. Yauk · 2022 · Archives of Toxicology
37. The Ontogeny of Cytochrome P450 Enzyme Activity and Protein Abundance in Conventional Pigs in Support of Preclinical Pediatric Drug Research
    J. Millecam, Laura De Clerck, E. Govaert, M. Devreese, Elke Gasthuys, W. Schelstraete, D. Deforce, L. De Bock, J. Van Bocxlaer, S. Sys et al. · 2018 · Frontiers in Pharmacology
38. A comparative evaluation of models to predict human intestinal metabolism from nonclinical data
    Estelle Yau, Carl Petersson, Hugues Dolgos, Sheila Annie Peters · 2017 · Biopharmaceutics & Drug Disposition
39. Investigation of omeprazole and phenacetin first‐pass metabolism in humans using a microscale bioreactor and pharmacokinetic models
    Thibault Bricks, J. Hamon, M. Fleury, R. Jellali, F. Merlier, Yves Edouard Herpe, Alexandre Seyer, J. Regimbeau, F. Bois, E. Leclerc · 2015 · Biopharmaceutics & drug disposition
40. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    M. Yoon, G. L. Kedderis, Grace Zhixia Yan, H. Clewell · 2015 · Toxicology
41. Biotransformation of Piceatannol, a Dietary Resveratrol Derivative: Promises to Human Health
    Yu Dai, Jin Xuan Lim, Samuel Chao Ming Yeo, Xiaoqiang Xiang, Kai Soo Tan, Jia Fu, Lizhen Huang, Hai‐Shu Lin · 2019 · Molecular Nutrition & Food Research
42. A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry
    Jerry L. Campbell, M. Andersen, H. Clewell · 2014 · Inhalation Toxicology
43. Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data
    Katherine L. Gill, Michael Gertz, J. Houston, A. Galetin · 2013 · Drug Metabolism And Disposition
44. Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors
    R. Laufer, O. G. Paz, A. DiMarco, F. Bonelli, E. Monteagudo, V. Summa, M. Rowley · 2009 · Drug Metabolism And Disposition
45. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics
    Sieto Bosgra, Maria L.H. Vlaming, Wouter H. J. Vaes · 2015 · Clinical Pharmacokinetics
46. A Targeted LC-MS/MS Proteomics-Based Strategy to Characterize In Vitro Models Used in Drug Metabolism and Transport Studies
    Mei-Juan Xu, N. Saxena, M. Vrana, Haeyoung Zhang, Vineet Kumar, S. Billington, Cyrus Khojasteh, S. Heyward, J. Unadkat, B. Prasad · 2018 · Analytical Chemistry
47. Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series
    Daga, Pankaj R., Bolger, Michael B., Haworth, Ian S., Clark, Robert D., Martin, Eric J. · 2018 · Molecular Pharmaceutics
48. Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance
    Varvara Gouliarmou, Alfonso Maria Lostia, Sandra Coecke, Camilla Bernasconi, Jos G.M. Bessems, J.L.C.M. Dorne, Stephen Ferguson, Emanuela Testai, Ursula Gundert‐Remy, James Brian. Houston et al. · 2018 · Toxicology in Vitro
49. New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate Staphylococcus aureus
    M. Durcik, A. E. Cotman, Žan Toplak, Š. Možina, Ž. Skok, P. Szili, M. Czikkely, E. Maharramov, T. Vu, M. Piras et al. · 2023 · Journal of Medicinal Chemistry
50. Stereological assessment of sexual dimorphism in the rat liver reveals differences in hepatocytes and Kupffer cells but not hepatic stellate cells
    Ricardo Marcos, Célia Cristina Carreiras Lopes, Fernanda Malhão, Carla Correia‐Gomes, Sónia Fonseca, Margarida Lima, Rolf Gebhardt, Eduardo Rocha · 2016 · Journal of Anatomy
51. Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation
    Yongmei Li, Jin Zhou, D. Ramsden, M. Taub, Drané O'Brien, Jun Xu, C. A. Busacca, N. Gonnella, D. Tweedie · 2014 · Drug Metabolism And Disposition
52. Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications
    J. Henshall, A. Galetin, A. Harrison, J. Houston · 2008 · Drug Metabolism And Disposition
53. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
    J. M. Brussee, Hui-Xin Yu, E. Krekels, Semra Palić, M. J. Brill, J. Barrett, A. Rostami-Hodjegan, S. N. de Wildt, C. Knibbe · 2018 · Pharmaceutical Research
54. Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.
    M. Di Nardo, E. Wildschut · 2018 · Journal of Thoracic Disease
55. Using a Vancomycin PBPK Model in Special Populations to Elucidate Case‐Based Clinical PK Observations
    Chie Emoto, Trevor N. Johnson, Brooks T. McPhail, Alexander A. T. M. M. Vinks, Tsuyoshi Fukuda · 2018 · CPT Pharmacometrics & Systems Pharmacology
56. The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model
    Helen Musther, Matthew D. Harwood, Jiansong Yang, David B. Turner, Amin Rostami‐Hodjegan, Masoud Jamei · 2017 · Journal of Pharmaceutical Sciences
57. The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development
    Aki T. Heikkinen, Floriane Lignet, Paul Cutler, Neil John Parrott · 2015 · PROTEOMICS - CLINICAL APPLICATIONS
58. Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and detoxification in humans as compared with rats.
    E. Martati, M. Boersma, A. Spenkelink, Dambar Bahadur Khadka, P. van Bladeren, I. Rietjens, A. Punt · 2012 · Toxicological Sciences
59. In Vitro- in Vivo Extrapolation of Hepatic Metabolism for Different Scenarios - a Toolbox.
    Sophia Krause, K. Goss · 2018 · Chemical Research in Toxicology
60. Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice
    Eman El‐Khateeb, Areti‐Maria Vasilogianni, Sarah Alrubia, Zubida M. Al‐Majdoub, Narciso A. S. Couto, Martyn Howard, Jill Barber, Amin Rostami‐Hodjegan, Brahim Achour · 2019 · Pharmacology & Therapeutics
61. Quantitative prediction and clinical evaluation of an unexplored herb–drug interaction mechanism in healthy volunteers
    Brandon T. Gufford, John T. Barr, Vanessa González-Pérez, Matthew E Layton, J. White, Nicholas H. Oberlies, M. Paine · 2015 · CPT: Pharmacometrics & Systems Pharmacology
62. Fragment-based discovery of focal adhesion kinase inhibitors.
    U. Grädler, J. Bomke, D. Musil, V. Dresing, M. Lehmann, G. Hölzemann, H. Greiner, C. Esdar, Mireille Krier, T. Heinrich · 2013 · Bioorganic & Medicinal Chemistry Letters
63. Rationalizing Underprediction of Drug Clearance from Enzyme and Transporter Kinetic Data: From In Vitro Tools to Mechanistic Modeling
    Aleksandra Galetin · 2014 · Methods in molecular biology
64. Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs.
    Katarina M. Nikolic, Danica Agababa · 2009 · Journal of Molecular Graphics and Modelling
65. Implementing In Vitro Bioactivity Data to Modernize Priority Setting of Chemical Inventories
    Marc A. Beal, M. Gagne, S. Kulkarni, G. Patlewicz, Russell S. Thomas, T. Barton-Maclaren · 2021 · ALTEX
66. Incorporating new approach methodologies in toxicity testing and exposure assessment for tiered risk assessment using the RISK21 approach: Case studies on food contact chemicals
    Alexandra E. Turley, Kristin Isaacs, Barbara A. Wetmore, Agnes L. Karmaus, Michelle R. Embry, Mansi Krishan · 2019 · Food and Chemical Toxicology
67. Structure-based optimization of non-peptidic Cathepsin D inhibitors.
    U. Grädler, P. Czodrowski, C. Tsaklakidis, M. Klein, D. Werkmann, S. Lindemann, K. Maskos, B. Leuthner · 2014 · Bioorganic & Medicinal Chemistry Letters
68. Evaluation and comparison of in vitro intrinsic clearance rates measured using cryopreserved hepatocytes from humans, rats, and rainbow trout.
    S. R. Black, J. Nichols, Kellie A. Fay, S. Matten, S. Lynn · 2021 · Toxicology
69. Evaluation of Human Interindividual Variation in Bioactivation of Estragole Using Physiologically Based Biokinetic Modeling
    Ans Punt, Suzanne M. F. Jeurissen, Marelle G. Boersma, Thierry Delatour, Gabriele Scholz, Benoı̂t Schilter, Peter J. van BLADEREN, Ivonne M.C.M. Rietjens · 2009 · Toxicological Sciences
70. From known knowns to known unknowns: predicting in vivo drug metabolites.
    O. Pelkonen, A. Tolonen, T. Korjamo, M. Turpeinen, H. Raunio · 2009 · Bioanalysis
71. Quantitation of Human Cytochrome P450 2D6 Protein with Immunoblot and Mass Spectrometry Analysis
    Ai‐Ming Yu, Jun Qu, Melanie Ann Felmlee, Jin Cao, Xi-Ling Jiang · 2008 · Drug Metabolism and Disposition
72. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds
    Aberra Fura, Viral P. Vyas, William Griffith Humphreys, Anjaneya Chimalokonda, David Rodrigues · 2008 · Biopharmaceutics & Drug Disposition
73. Physiologically-Based Pharmacokinetics
    Masoud Jamei, Karen Rowland Yeo, Trevor N. Johnson, Cyrus Ghobadi, Manoranjenni Chetty, Khaled Abduljalil, Gaohua Lu, Farzaneh Salem, Adam S. Darwich, Amin Rostami‐Hodjegan · 2011 · Springer eBooks
74. Assessment of the predictive capacity of a physiologically based kinetic model using a read-across approach
    A. Paini, Andrew Paul Worth, S. Kulkarni, D. Ebbrell, J. Madden · 2021 · Computational Toxicology
75. Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes
    C. Wegler, P. Matsson, Veronica Krogstad, J. Urdzik, H. Christensen, T. Andersson, P. Artursson · 2021 · Molecular Pharmaceutics
76. Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics forin vitro–in vivoextrapolation of drug metabolism and transport and considerations in selecting appropriate techniques
    Hajar Al Feteisi, Brahim Achour, Amin Rostami‐Hodjegan, Jill Barber · 2015 · Expert Opinion on Drug Metabolism & Toxicology
77. Physiologically Based Toxicokinetic Modelling as a Tool to Support Risk Assessment: Three Case Studies
    H. Mielke, U. Gundert-Remy · 2012 · Journal of Toxicology
78. Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy
    Yongchuan Gu, Malcolm Drummond Tingle, William Robert Wilson · 2011 · Journal of Pharmacology and Experimental Therapeutics
79. Correlating in vitro data to in vivo findings for risk assessment.
    A. S. Bale, E. Kenyon, T. Flynn, J. Lipscomb, D. Mendrick, T. Hartung, G. W. Patton · 2014 · ALTEX
80. CYP2D6 is primarily responsible for the metabolism of clomiphene.
    C. Ghobadi, A. Gregory, H. Crewe, A. Rostami-Hodjegan, M. Lennard · 2008 · Drug Metabolism and Pharmacokinetics
81. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation
    Yoko Franchetti, Thomas D. Nolin · 2020 · The Journal of Clinical Pharmacology
82. Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone
    Miaoying Shi, Hans Bouwmeester, Ivonne M.C.M. Rietjens, Marije Strikwold · 2020 · Archives of Toxicology
83. Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties
    C. Bowman, L. Benet · 2019 · Pharmaceutical Research
84. Quantifying gut wall metabolism: methodology matters
    O. Hatley, Christopher R. Jones, A. Galetin, A. Rostami-Hodjegan · 2017 · Biopharmaceutics & drug disposition
85. Matrix Modulation of the Bioactivation of Estragole by Constituents of Different Alkenylbenzene-containing Herbs and Spices and Physiologically Based Biokinetic Modeling of Possible In Vivo Effects
    Wasma Alhusainy, Suzanne J. P. L. van den Berg, Alicia Paini, Adelaine Campana, Mariska Asselman, Albertus Spenkelink, Ans Punt, Gabriele Scholz, Benoı̂t Schilter, Timothy B. Adams et al. · 2012 · Toxicological Sciences
86. Metabolism of Oxycodone in Human Hepatocytes from Different Age Groups and Prediction of Hepatic Plasma Clearance
    T. Korjamo, A. Tolonen, V. Ranta, M. Turpeinen, H. Kokki · 2012 · Frontiers in Pharmacology
87. Hepatic bile acid synthesis and secretion: Comparison of in vitro methods
    Véronique M P de Bruijn, Zhenguo Wang, Wouter Bakker, Weijia Zheng, Bart Spee, Hans Bouwmeester · 2022 · Toxicology Letters
88. Scaling Factors for Clearance in Adult Liver Cirrhosis
    Eman El-Khateeb, B. Achour, D. Scotcher, Z. Al-Majdoub, V. Athwal, J. Barber, A. Rostami-Hodjegan · 2020 · Drug Metabolism And Disposition
89. QSARs for estimating intrinsic hepatic clearance of organic chemicals in humans.
    A. Pirovano, S. Brandmaier, M. Huijbregts, A. Ragas, K. Veltman, A. Hendriks · 2016 · Environmental Toxicology and Pharmacology
90. Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans
    C. Gibson, P. Lu, C. Maciolek, Christen Wudarski, Z. Barter, K. Rowland-Yeo, M. Stroh, E. Lai, D. Nicoll-Griffith · 2013 · Xenobiotica; the fate of foreign compounds in biological systems
91. Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors
    Yuan-hua Lu, Jin-bo Yang, Haiyan Zhang, Jin Yang · 2013 · Clinical Pharmacokinetics
92. Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa
    R. Thelingwani, Kariema Dhansay, Peter J. Smith, K. Chibale, C. Masimirembwa · 2012 · Xenobiotica; the fate of foreign compounds in biological systems
93. Acetylcholinesterase Inhibition in Rats and Humans Following Acute Fenitrothion Exposure Predicted by Physiologically Based Kinetic Modeling-Facilitated Quantitative In Vitro to In Vivo Extrapolation
    Jiaqi Chen, Shensheng Zhao, S. Wesseling, Nynke I. Kramer, I. Rietjens, Hans Bouwmeester · 2023 · Environmental Science and Technology
94. Physiologically Based Kinetic Modeling-Facilitated Reverse Dosimetry to Predict In Vivo Red Blood Cell Acetylcholinesterase Inhibition Following Exposure to Chlorpyrifos in the Caucasian and Chinese Population
    Shensheng Zhao, L. Kamelia, Rungnapa Boonpawa, S. Wesseling, B. Spenkelink, I. Rietjens · 2019 · Toxicological Sciences
95. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
    Dwaipayan Mukherjee, Jiuhong Zha, Rajeev M Menon, Mohamad Shebley · 2018 · Journal of Pharmacokinetics and Pharmacodynamics
96. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity
    M. Strikwold, B. Spenkelink, R. Woutersen, I. Rietjens, A. Punt · 2017 · Toxicological Sciences
97. Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors
    O. Hatley, Christopher R. Jones, A. Galetin, A. Rostami-Hodjegan · 2017 · Biopharmaceutics & drug disposition
98. Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model.
    Rodrigo Cristofoletti, Naseem A. Charoo, J. Dressman · 2016 · Journal of Pharmacy and Science
99. Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
    Alan F. Sasso, P. Schlosser, G. L. Kedderis, M. Genter, J. Snawder, Zheng Li, S. Rieth, J. Lipscomb · 2013 · Toxicological Sciences
100. Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes
     H. F. Perrett, Zoe E. Barter, B. C. Jones, Hiroshi Yamazaki, GT Tucker, Amin Rostami‐Hodjegan · 2007 · Drug Metabolism and Disposition